BridgeBio Pharma BBIO Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's deferred revenue?
- BridgeBio Pharma (BBIO) reported deferred revenue of $6.12M in Q1 2026.
- How has BridgeBio Pharma's deferred revenue changed year-over-year?
- BridgeBio Pharma's deferred revenue decreased by 65.1% year-over-year, from $17.51M to $6.12M.
- What does deferred revenue mean?
- Cash received in advance for services or products that the company has not yet provided.
- How do you interpret deferred revenue?
- An increase signals successful business development and partnership deals, while a decrease indicates the recognition of revenue over time.
- How does deferred revenue compare across companies?
- High deferred revenue is a positive indicator of successful partnership strategy and future revenue recognition potential.